Gilead Sciences is devoting another $200 million to its existing partnership with Arcellx the biotechnology companies said Wednesday. Kite, a Gilead (ticker: GILD) company, has exercised an option to negotiate a license for Arcellx ‘s ARC-SparX program, ACLX-001, in multiple myeloma. The companies said they also expanded the scope of their collaboration for...
A series of 1-2 are under construction to make a big change in ACLX. I wait for the next candle formation to find a bullish pattern. Maybe a morning star. Keep watching.